Fox Run Management L.L.C. Purchases Shares of 19,003 TG Therapeutics, Inc. $TGTX

Key Points

• Fox Run Management L.L.C. acquired a new stake in TG Therapeutics, purchasing 19,003 shares valued at approximately $749,000 in the first quarter.
• Several hedge funds, including Soleus Capital Management and Northern Trust Corp, increased their stakes in TG Therapeutics during the fourth quarter, reflecting growing institutional investment in the company.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a target price of $37.00, while the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.25.

Fox Run Management L.L.C. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 19,003 shares of the biopharmaceutical company's stock, valued at approximately $749,000.

A number of other institutional investors have also recently bought and sold shares of TGTX. Envestnet Asset Management Inc. raised its holdings in shares of TG Therapeutics by 11.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 50,111 shares of the biopharmaceutical company's stock worth $1,508,000 after acquiring an additional 5,135 shares during the period. Russell Investments Group Ltd. boosted its stake in TG Therapeutics by 323.2% in the 4th quarter. Russell Investments Group Ltd. now owns 34,706 shares of the biopharmaceutical company's stock worth $1,045,000 after purchasing an additional 26,506 shares during the period. Bank of Montreal Can increased its holdings in TG Therapeutics by 7.3% during the 4th quarter. Bank of Montreal Can now owns 20,016 shares of the biopharmaceutical company's stock worth $602,000 after purchasing an additional 1,357 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at about $14,508,000. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after purchasing an additional 463 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

TGTX stock traded up $0.2550 during trading hours on Friday, reaching $29.0250. The stock had a trading volume of 594,028 shares, compared to its average volume of 2,481,830. The stock has a market capitalization of $4.61 billion, a PE ratio of 78.30 and a beta of 1.95. The stock has a 50-day simple moving average of $34.23 and a 200 day simple moving average of $35.71. TG Therapeutics, Inc. has a fifty-two week low of $21.11 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same period in the previous year, the company posted $0.04 earnings per share. The firm's revenue for the quarter was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity

In other news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.64% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.